MARKET INTRODUCTION
Vaccines have achieved a significant consideration in the medical field to treat and infectious diseases. Infectious vaccines are given to children at an early to build immunity against the diseases. Various organizations such as WHO and UNICEF are putting their efforts to increase vaccination against infectious diseases. According to their latest report published in July 2021, there is a decline in the rate of deaths from polio and measles by 73% worldwide between 2000 and 2021.
MARKET DYNAMICS
The infectious vaccines market growth is anticipated to grow due to rising incidences of infectious diseases, increasing government awareness campaigns to enhance vaccine distribution, and growing research and development for vaccines by top leaders operating the market. The outbreak of coronavirus has created vital growth opportunities for market growth and is likely to mark significant growth in the coming years.
MARKET SCOPE
The "Infectious Vaccines Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of infectious vaccines market with detailed market segmentation by type, disease and distribution channel. The infectious vaccines market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in infectious vaccines market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The infectious vaccines market is segmented on the basis of, type, disease and distribution channel. Based on type, the market is divided into inactivated vaccines, live attenuated vaccines, DNA and recombinant vector vaccines, and others. Based on disease, the market is divided into typhoid, tuberculosis, tetanus and diphtheria, influenza, hepatitis, polio, and others. And based on distribution channel, the market is classified as hospitals and retail pharmacies, and online distribution.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the infectious vaccines market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The infectious vaccines market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting infectious vaccines market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the infectious vaccines market in these regions.
MARKET PLAYERS
The report covers key developments in the infectious vaccines market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from infectious vaccines market are anticipated to have lucrative growth opportunities in the future with the rising demand for infectious vaccines in the global market. Below mentioned is the list of few companies engaged in the infectious vaccines market.
The report also includes the profiles of key players in infectious vaccines market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- GlaxoSmithKline plc.
- Novartis AG
- Merck and Co, Inc.
- Sanofi
- Pfizer Inc.
- Johnson and Johnson, Services Inc.
- Daiichi Sankyo
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Emergent BioSolutions Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Infectious Vaccines Report Scope
Report Attribute | Details |
---|---|
Market size in 2023 | US$ XX Million |
Market Size by 2031 | US$ XX Million |
Global CAGR (2023 - 2031) | XX% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies
1. GlaxoSmithKline plc.
2. Novartis AG
3. Merck and Co, Inc.
4. Sanofi
5. Pfizer Inc.
6. Johnson and Johnson, Services Inc.
7. Daiichi Sankyo
8. Takeda Pharmaceutical Company Limited
9. CSL Limited
10. Emergent BioSolutions Inc.
1. GlaxoSmithKline plc.
2. Novartis AG
3. Merck and Co, Inc.
4. Sanofi
5. Pfizer Inc.
6. Johnson and Johnson, Services Inc.
7. Daiichi Sankyo
8. Takeda Pharmaceutical Company Limited
9. CSL Limited
10. Emergent BioSolutions Inc.